Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

DanCann Pharma A/S has secured 71 percent of the TO 2’s

COPENHAGEN, Denmark, 26 May 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announces that they today received underwriting commitments of approximately DKK 5.6 million, regarding subscription options of series TO 2 ("TO 2"), meaning that approximately 71 percent of the issue volume in TO 2 is guaranteed.The number of TO 2s amounts to 21,927,810, whereby each (1) TO 2 entitles the holder to subscribe for one (1) new share in the Company at a subscription price of DKK 0.36 during the period from 16

Cereno Scientific AB announces outcome in the company’s rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY,  WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Cereno Scientific AB (publ) ("Cereno Scientific" or the "Company") has completed the rights issue of units, consisting of shares of series B and warrants of series TO3, which the board

Frontier markets are facing a credit crunch and heightened risk of debt distress

During the last decade, new sources of financing opened, especially for those lower-income countries catching up with emerging economies, many of which are called frontier markets[1]. The decade after the global financial crisis was characterized by ample liquidity and low interest rates in global financial markets and leading to investors seeking yield in riskier markets. At the same time, China significantly increased its overseas lending, specifically targeting emerging and developing economies. China’s agenda was to ensure access to natural resources needed to spur its fast growth and

DanCann Pharma A/S has successfully completed pre-validation batches and expects final approval from the Danish Medicines Agency by the end of summer

COPENHAGEN, Denmark, 26 May 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, is pleased to announce the completion of its pre-validation batches. These batches are paving the way for the Company's forthcoming application to the Danish Medicines Agency for its final inspection of Biotech Pharm1 (“BP1”), seeking approval for the release of its products. This achievement aligns closely with the Company's original expectations, with minor adjustments made along the way.As communicated in December 2022, three

1st Quarter Results and Outline of 2023 Workplan

("Amaroq" or the "Corporation" or the "Company") 1[st] Quarter Financial Results and Outline of 2023 Workplan TORONTO, ONTARIO - [26] May 2023 - Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ First North: AMRQ), an independent mine development company with a substantial land package of gold and strategic mineral assets covering an area of 7,866.85 km[2] in Southern Greenland, is pleased to present its Q1 2023 Financial Results and outline its current workplan for 2023. Q1 2023 Corporate Highlights: · Debt funding non-binding term sheets for a $66.8 million (US$49.5 million) senior

Acuvi strengthens management team with new CTO

The Acuvi leadership team gets a boost with the joining of Karin Thurberg as CTO. Karin is a long-time telecom industry heavyweight having served in senior management positions in companies like Ericsson and Huawei. She has a background of having led sales roles as well as business development and product development functions in major technology companies.Acuvi is poised to strengthen its position in the sector with the upcoming launch of its high-tech micromotor platform ULTRA. This revolutionary miniature platform delivers nanometer precision combined with the best power ratio in its

Nordic Capital appoints Mohit Agnihotri as new Partner

Significant addition to Nordic Capital Advisors’ leading Technology & Payments team Nordic Capital Advisors has today announced the appointment of Mohit Agnihotri as a Partner.  Mohit has over two decades of investment banking, investing and consulting experience in Financial Technology, Payments and broader Software & Technology sectors.  He will now become a key member of Nordic Capital Advisors’ leading Technology & Payments team and will be based in London.Mohit has extensive transactional experience in the Fintech, Payments and Software sectors globally through his previous

Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy

26 May 2023  Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy DUO-E is the first global Phase III trial of immunotherapy plusPARP inhibition to demonstrate clinical benefit in this setting Positive high-level results from the DUO-E Phase III trial showed Imfinzi (durvalumab) in combination with platinum-based chemotherapy followed by either Imfinzi plus Lynparza (olaparib) or Imfinzi alone as maintenance therapy both demonstrated a statistically significant and clinically

The subscription period in Bioservo’s rights issue begins today

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS DOCUMENT DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURISDICTION.Today, May 26, 2023, the subscription period in Bioservo Technologies AB’s (“Bioservo” or the “Company”) rights issue of approximately MSEK 37 begins, which was resolved by the board of directors of Bioservo on May 15, 2023, based on the authorisation of the

HC Andersen Capital Events 26/5: Meet the management in Tryg, Qlife and GomSpace

HC Andersen Capital is today hosting digital events where you can meet and ask questions directly to the top management. It is free for all to attend.How does Tryg work with innovation?Get updated on how the insurance company Tryg works with innovation when we host an event about this specific subject.From Tryg we have COO and member of the group management Lars Bonde, who for many years has been responsible for IT and Nordic Innovation - Lars will update us on how Tryg works with new services and products. The event will be held in Danish.Disclaimer: HC Andersen Capital receives

DanCann Pharma A/S in advanced talks with new investor of additional DKK 12 million for topping up the outcome of the TO 2’s

COPENHAGEN, Denmark, 26 May 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby inform the market and its investors that it is currently engaged in advanced discussions with a new investor regarding an additional DKK 12 million to supplement the outcome of TO 2's. The agreement is based on a loan agreement with conversion options and initially has a scope of DKK 12 million, which can potentially increase to a total of DKK 18 million. The agreement will be subject to an approval on an Extra General Meeting.

Hamlet Pharma AB (publ): Q3 Interim Report January 2023 – March 2023

Opening remarks   During the third quarter of the fiscal year, Hamlet Pharma has continued its clinical trial program for Alpha1H, a drug candidate in the HAMLET family, as a standalone treatment for bladder cancer patients. The company has also continued its collaboration with Neurochase for the treatment of brain tumors with Alpha1H.   Hamlet Pharma has also successfully completed its Horizon 2020 project, receiving the last part of the grant, which means full funding. The European Commission commended Hamlet Pharma for its progress and stated that the project had fully

Awarding the Munin jacket

Aker BP (OSE:AKRBP, OTCQX:AKRBF) has awarded Heerema Vlissingen a contract for procurement and construction for the Munin jacket in the Yggdrasil area.   “This is an important contract for the Yggdrasil development. With this award we have placed all major fixed facilities contracts in the Yggdrasil area, and we are in line with our execution plan,” states Project Director Peter Kupka for fixed facilities deliveries in Yggdrasil.   “Heerema Fabrication Group Vlissingen is an experienced international contractor with a solid track record. I am very pleased that they will

Genetic Analysis AS: Mandatory notification of trade – Primary Insiders

OSLO, NORWAY – 26 May 2023: Genetic Analysis AS (“GA” or “the Company”) announces that a member of the management has bought GEAN-shares.Ronny Hermansen, CEO of Genetic Analysis AS, has through the fully owned company InVitroDia AS yesterday bought 33.250 GEAN shares at an average price of 1,71 NOK per share. The shares were acquired on the Spotlight Stock Market. Following the transaction, Ronny Hermansen including controlled company owns 225.290 shares and 26.909 tradable subscription rights GEAN T02.

Invitation to Huddlestock’s Q1 2023 presentation & capital markets day on 1 June 2023

Bricknode has the pleasure of extending an invite to investors, analysts and media to join Huddlestock’s Q1 2023 presentation & capital markets day on 1 June 2023, 12:00 – 14:00 CEST. The event will be hosted by Huddlestock’s CEO John E. Skajem, together with members of the executive management team.Bricknode completed the sale of all its operational assets to Huddlestock on 4 April, as previously announced. The capital markets day will include discussion about Huddlestock’s first quarter 2023 financial results, followed by an update on the company’s strategy and growth opportunities in

Navamedic to own a total of 96.33 per cent of shares in Sensidose following closing of public offer

Oslo, 26 May 2023 – Following the closing of the acceptance period in the previously announced public offer, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, will become the owner of 96.33 per cent of the share capital and votes and 93.16 per cent of the series TO 1 warrants ("Warrants") in Sensidose Aktiebolag ("Sensidose).This is an important milestone in Navamedic’s plan to acquire all outstanding shares and include Sensidose’s product offering in its well proven and highly scalable market access platform for

Greenfood’s Interim report first quarter 2023

The first quarter of the year represents a strong start to 2023. Group sales are up 20.7% and Adjusted EBITDA almost doubled.INTERIM OVERVIEW 1 JANUARY - 31 MARCH · Net sales for the period totalled SEK 1,450.1 million (1,201.0) an increase of 20.7%. Out of the increase of SEK 249.1 million, SEK 112.4 million increase is generated at Picadeli, mainly due to a larger established base of buying stores. · Adjusted EBITDA was with SEK 42.4 million (22.3) significantly better than the first quarter 2022. The main driver is Picadeli with a SEK 18.2 million increase, caused by increased

Navamedic announces the final outcome in the offer to the shareholders and holders of warrants of series TO 1 in Sensidose Aktiebolag

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or USA, or in any other jurisdiction where such offer pursuant to legislation, restrictions and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders and Warrant Holders (as defined below) not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders and Warrant Holders should refer to the offer

Orders of NOK 8.2m received to date, representing annual recurring sales potential of approx NOK 50 million

Oslo, 26 May 2023 – Observe Medical ASA (the "Company" or "Observe Medical") has received initial orders from distributors for delivery of UnoMeter™ products and is expecting to ship the first units to customers in June. The total value of these initial orders is NOK 8.2 million. The distributors that have signed the orders have historically had annual repetitive purchases of around NOK 50 million. Dialogues with these and other distributors continue to advance, and with products expected to be on the market relatively soon, Observe Medical is expecting additional orders to be confirmed.

GomSpace Q1 2023 Report and Status Update

GomSpace releases its Q1 2023, and the CEO outlines plans for bringing the company to profitabilityFIRST QUARTER OF 2023 · Order intake was T.SEK 33,454 (41,497) · Net revenues of T.SEK 78,150 are in line with Q1 2022 (78,365) · Gross margin this quarter is positive 12%, compared to negative 26% for full year 2022 · Operating profit (EBIT) decreased to negative T.SEK 14,078 (4,166) · Earnings per share were negative SEK 0.24 (SEK 0.06) Main events: · Changed model for market guidance from Revenue and EBIT, to focus on Free Cashflow. The guidance for a free cash flow

Betolar's solution supports Indian architects, real estate developers and contractors in the green transition

Friday, 26 May 2023, Ahmedabad, India. Betolar's Indian partner, Vyara Tiles, will launch locally produced low-carbon concrete products with the Geoprime® solution at the ACE Reflect event in Ahmedabad, India, on May 26-27, 2023, targeting architects, designers, and property developers. "In our environmentally friendly construction products developed with Vyara Tiles, cement has been completely replaced with circular economy materials, drastically reducing their CO2 emissions. The green transition requires a change in thinking throughout the value chain, from ordering to construction,"

ShaMaran Corporate Update

VANCOUVER, BC, May 25, 2023 /CNW/ - ShaMaran Petroleum Corp. (TSX Venture and Nasdaq First North: SNM) (“ShaMaran Petroleum” or the “Company”) has granted incentive stock options to certain officers, employees and other eligible persons of the Company to acquire 29,400,000 shares of the Company at an exercise price of CAD$0.063 per share.  The options are exercisable, subject to vesting provisions, over a period of five years.  ShaMaran has also granted 19,750,000 restricted share units at a price of CAD$0.063 to certain officers, employees and other eligible persons of the Company.  The

CHOSA Oncology AB presents clinical phase 2 results of LiPlaCis and its Drug Response Predictor test at ASCO 2023

CHOSA Oncology AB today publishes results from the prospective phase 2 study of LiPlaCis® (a liposomal formulation of cisplatin) in previously heavily treated patients with metastatic breast cancer as the abstract is being released on the ASCO website on May 25, 2023, at 5:00 PM (ET) / 23:00 CET (please see a link to ASCO’s website below). This patient group was tested using the diagnostic tool Drug Response Prediction (DRP®), which is a 205 mRNA biomarker signature, that assesses whether the patient is likely to respond to cisplatin treatment - or not. The results show that patients who get

There are no items matching the current filter
There are no more items matching the current filter
Back to top